Provided by Tiger Trade Technology Pte. Ltd.

Rani Therapeutics Holdings

0.7955
+0.00450.57%
Post-market: 0.80000.0045+0.57%17:39 EDT
Volume:483.88K
Turnover:396.01K
Market Cap:110.89M
PE:-3.66
High:0.8517
Open:0.8190
Low:0.7911
Close:0.7910
52wk High:3.87
52wk Low:0.4453
Shares:139.40M
Float Shares:85.67M
Volume Ratio:0.97
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2174
EPS(LYR):-0.4500
ROE:-172.15%
ROA:-52.99%
PB:2.83
PE(LYR):-1.77

Loading ...

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)

TIPRANKS
·
Jul 16

Rani Therapeutics reports initial data from RT-114 study

TIPRANKS
·
Jul 15

Rani Therapeutics Says Oral Rt-114 Obesity Drug Candidate Tops Matched Injection Exposure in Phase 1a Data

Reuters
·
Jul 15

Rani Therapeutics Announces Positive Initial Phase 1a Data for Rt-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - Phase 1a Study Expanded with Additional Cohort to Define Pharmacokinetic Relationship

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - no Adverse Events Attributed to Ranipill Capsule; Treatment-related Events were Mild

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - Phase 1B Study Expected to Begin in 2026 with Data Anticipated in 2027

THOMSON REUTERS
·
Jul 15

Rani Therapeutics Announces R&D Collaboration with Pegbio

Reuters
·
Jul 10

Rani Therapeutics announces research, development collaboration with PegBio

TIPRANKS
·
Jul 10

Rani Therapeutics Partners with Pegbio to Develop Oral Obesity Drug Candidates

Reuters
·
Jul 10

Rani Therapeutics Announces Research and Development Collaboration with Pegbio to Expand Obesity Pipeline Across Multiple Novel Candidates

THOMSON REUTERS
·
Jul 10

Rani Therapeutics Holdings - Co and Pegbio to Develop Ranipill Formulations for Multiple Obesity Candidates

THOMSON REUTERS
·
Jul 10

Rani Therapeutics Files Form 3 for CFO Nicholas Maestas on Initial Beneficial Ownership Statement

Reuters
·
Jul 09

Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford

Reuters
·
Jun 29

Rani Therapeutics Holdings - Nicholas Maestas Succeeds Svai Sanford as Chief Financial Officer

THOMSON REUTERS
·
Jun 29

Rani Therapeutics stockholders elect directors at annual meeting

Reuters
·
May 29

Rani Therapeutics Announces $20 Million Equity Financing

TIPRANKS
·
May 27

Rani Therapeutics prices USD 20 million registered direct stock offering at USD 1.07 per share

Reuters
·
May 26

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class a Common Stock Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 26

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
May 26